Efficacy and safety of Levodopa-Carbidopa Intestinal Gel in the treatment of Parkinson’s Disease
Objective: Our study aims to analyze the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) in Parkinson's disease (PD). Background: Oral Levodopa is considered to…Effects of levodopa dose on temporal dynamics of cortical activity and postural control in people with Parkinson’s disease
Objective: The purpose of this study was to evaluate the temporal dynamics of cortical activity and postural control for the first levodopa dose of the…Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…Effect of H. pylori Infection on L-DOPA Pharmacokinetics in Patients with Parkinson’s disease.
Objective: To evaluate whether Helicobactor pylori (H.pylori) infection affects the pharmacokinetics of L-DOPA in patients with Parkinson’s disease (PD). Background: H. pylori infects gastric mucosa…Quantitative 3D movement analysis detects motor improvement earlier than MDS-UPDRS in a levodopa challenge test
Objective: Characterize the response of gait in a levodopa challenge test (LCT) in PD using inertial sensor-based 3D movement analysis and MDS-UPDRS. Background: Quantitative 3D…CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)
Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial
Objective: To assess the long-term effectiveness of LCIG monotherapy on reducing daily health-state fluctuations and time to on without troublesome dyskinesia (ONwoTD) after waking Background:…Effects of Angiotensin Type 1 Receptor Antagonists on Parkinson’s Disease Progression: an exploratory study in the PPMI database
Objective: The objective of this study is to analyze the effect of exposure to AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) on the clinical…Subcutaneous Levodopa Infusion for Parkinson’s disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
Objective: To review one-year exploratory efficacy data from the ND0612 BeyoND study. Background: ND0612 is an investigational subcutaneous delivery system providing minimally invasive, continuous infusion…Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel
Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 57
- Next Page »